ADARx Pharmaceuticals is a technology company.
ADARx Pharmaceuticals is a technology company.
ADARx Pharmaceuticals has raised $321.0M across 3 funding rounds.
ADARx Pharmaceuticals has raised $321.0M in total across 3 funding rounds.
ADARx Pharmaceuticals has raised $321.0M in total across 3 funding rounds.
ADARx Pharmaceuticals's investors include Andreessen Horowitz, Frazier Healthcare Partners, Ed Mathers, OrbiMed, SR One, Third Rock Ventures.
ADARx Pharmaceuticals is a clinical-stage biotechnology company headquartered in San Diego, California, founded in 2019, focused on developing next-generation RNA therapeutics to treat genetic, cardiometabolic, central nervous system, complement-mediated, cardiovascular, and metabolic diseases.[1][3][4] The company builds a proprietary RNA targeting platform featuring oligonucleotides for inhibition, degradation, and editing, paired with novel delivery technologies, serving patients with serious unmet needs in rare and common diseases through a diverse clinical-stage pipeline including ADX-324 (Phase 2 for Hereditary Angioedema), ADX-038 (Phase 2 for Paroxysmal Nocturnal Hemoglobinuria), and ADX-850 (Phase 1 for Essential Hypertension).[1][2][3] With $286M in total funding, including a $200M oversubscribed Series C led by investors like TCGX, ADARx demonstrates strong growth momentum, advancing multiple programs toward potentially transformative treatments with improved potency, precision, and durability.[1]
ADARx Pharmaceuticals emerged in 2019 from breakthroughs in RNA science, building on the 2006 Nobel Prize-winning discovery of RNA interference (RNAi) by Dr. Andrew Fire and Dr. Craig Mello, which unlocked gene-silencing mechanisms.[1][5] Led by President and CEO Zhen Li and CFO Ajim Tamboli, the company was founded to harness endogenous enzymes like ADAR for precise mRNA base editing, targeting single-point mutations to restore functional proteins.[2][6] Early traction came from developing a versatile RNA platform, culminating in significant funding milestones like the recent $200M Series C, supported by a board including experts such as Lorence Kim, Simeon J. George, and Carl L. Gordon, fueling rapid pipeline expansion into clinical stages.[1][6]
ADARx stands out in RNA therapeutics through proprietary technologies emphasizing precision and versatility:
ADARx rides the explosive growth of RNA therapeutics, amplified by RNAi pioneers' foundational work and recent successes like mRNA vaccines, positioning it to disrupt treatments for hard-to-drug diseases amid rising demand for precision genetic medicines.[3][5] Timing is ideal with advancing clinical data in complement-mediated (e.g., Hereditary Angioedema) and cardiometabolic areas, fueled by market forces like aging populations, genetic testing proliferation, and investor enthusiasm—evident in its $200M Series C amid a biotech funding resurgence.[1][2] ADARx influences the ecosystem by pioneering endogenous enzyme-based editing (e.g., ADAR-mediated), potentially expanding RNA's reach beyond silencing to correction, inspiring competitors and collaborators in biotech hubs like San Diego.[1][4][5]
ADARx is primed for milestone readouts from Phase 2 trials of ADX-324 and ADX-038 in 2026, potentially validating its platform and unlocking further funding or partnerships, while preclinical assets like RNA editing for Alpha-1 Antitrypsin Deficiency advance toward clinic.[2][3] Trends like AI-driven drug design and next-gen delivery will accelerate its pipeline, evolving its role from innovator to leader in durable RNA medicines for chronic diseases. As a biotech trailblazer turning cutting-edge RNA science into life-saving therapeutics, ADARx exemplifies how precision platforms can redefine patient outcomes in an era of genetic medicine.[1][5]
ADARx Pharmaceuticals has raised $321.0M across 3 funding rounds. Most recently, it raised $200.0M Series C in August 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2023 | $200.0M Series C | Andreessen Horowitz, Frazier Healthcare Partners, Ed Mathers, OrbiMed, SR One, Third Rock Ventures | |
| Jan 1, 2023 | $46.0M Series B | Andreessen Horowitz, Frazier Healthcare Partners, Ed Mathers, OrbiMed, SR One, Third Rock Ventures | |
| Sep 1, 2021 | $75.0M Series B | Andreessen Horowitz, Frazier Healthcare Partners, Ed Mathers, OrbiMed, SR One |